Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Company Overview - Annexon Biosciences is focused on classical complement and is pioneering first-in-kind programs targeting immune inflammation across various diseases affecting the body, brain, and eye [3]. Product Development - The company is developing a program for Guillain-Barré syndrome, which is the first and only program in this space in the last 50 years, demonstrating landmark unprecedented data in improving patient outcomes [4].